News

CT Culture Corner: Actor Paul Giamatti's CT roots run as deep as his list of credits
CT Culture Corner is a weekly look inside the culture, arts and entertainment world in Greater Waterbury, Litchfield County ...
MedPage Today on MSN3d
Managing Psychiatric and Behavioral Problems With Alzheimer's Disease
As Alzheimer's disease progresses, behavioral and psychiatric issues become common, distressing, and even dangerous for ...
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Surpasses 50% Enrollment Target
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study ...
Waterbury museum program brings art and connection to those facing Alzheimer’s
Over the last year, a CT man and his wife have driven to Waterbury to make art with others living with early-stage ...
Combating brain diseases using polymer-based targeted drug delivery
The human brain comprises billions of neurons, synapses, and cell types, making it one of the universe's most intricate and ...
Odessa American5d
Doctor: Early detection of dementia crucial
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
How do the new antibody drugs for Alzheimer’s disease work?
In one clinical trial published in the Journal of the American Medical Association (JAMA) in 2023, 24% of people receiving donanemab had side-effects including brain swelling ... either a PET-CT scan ...
Cognition Therapeutics, Inc.: Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer's Disease
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders ...